U.S. after-hours trading on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinical milestones or recent data presentations, others climbed despite having no new corporate developments, reflecting renewed interest in high-volatility biotech names during extended trading.
Below are the notable after-hours gainers:
Agape ATP Corp. (ATPC) — Up 29.41% After HoursAfter hours: $0.088 (+29.41%) Close: $0.0680 (-94.83%)
Agape ATP surged in after-hours trading despite no company-specific news on Wednesday. The move appears to be part of a broader risk-on reaction in micro-cap names following the Fed's rate cut, which improved sentiment across speculative segments of the market.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Up 12.76% After HoursAfter hours: $11.57 (+12.76%) Close: $10.26 (+1.58%)
Corbus gained momentum ahead of a key clinical update. The company announced plans to release results from its Phase 1a SAD/MAD study of CRB-913 before the market opens on Thursday, December 11, 2025, followed by an 8:00 a.m. ET conference call. Anticipation around the data likely contributed to the strong after-hours move.
Anebulo Pharmaceuticals, Inc. (ANEB) — Up 8.37% After HoursAfter hours: $2.33 (+8.37%) Close: $2.15 (-6.52%)
Anebulo rebounded sharply after hours despite no news on Wednesday. The gain aligns with the broader uptick in small-cap biotech sentiment following the Fed's rate decision.
Cue Biopharma, Inc. (CUE) — Up 13.12% After HoursAfter hours: $0.54 (+13.12%) Close: $0.4773 (-3.50%)
Cue Biopharma posted a double-digit after-hours jump with no new corporate developments. The move appears to be macro-driven as investors rotated back into beaten-down biotech names.
Curis, Inc. (CRIS) — Up 7.68% After HoursAfter hours: $1.3999 (+7.68%) Close: $1.30 (-2.26%)
Curis traded higher after hours, extending momentum from its updated clinical data presented on December 9 at the 67th ASH Annual Meeting. The poster highlighted progress in the company's frontline AML triplet study (CA-4948-104), which continues to draw investor attention.
Skye Bioscience, Inc. (SKYE) — Up 7.02% After HoursAfter hours: $1.22 (+7.02%) Close: $1.14 (-5.79%)
Skye Bioscience saw a modest after-hours recovery despite no news on Wednesday, likely benefiting from the broader biotech lift tied to the Fed-driven market rally.
Cerus Corporation (CERS) — Up 3.17% After HoursAfter hours: $1.95 (+3.17%) Close: $1.89 (+1.61%)
Cerus continued its upward trend after announcing a group purchasing agreement with Blood Centers of America (BCA). The deal covers the company's full INTERCEPT product line and aims to expand access to pathogen-reduction technologies across BCA's nationwide network.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.